Cargando…
EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653125/ https://www.ncbi.nlm.nih.gov/pubmed/33209593 http://dx.doi.org/10.21037/tlcr-2020-13 |
| _version_ | 1783607837575872512 |
|---|---|
| author | Steuer, Conor E. Ramalingam, Suresh S. |
| author_facet | Steuer, Conor E. Ramalingam, Suresh S. |
| author_sort | Steuer, Conor E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7653125 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76531252020-11-17 EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic? Steuer, Conor E. Ramalingam, Suresh S. Transl Lung Cancer Res Editorial AME Publishing Company 2020-10 /pmc/articles/PMC7653125/ /pubmed/33209593 http://dx.doi.org/10.21037/tlcr-2020-13 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Steuer, Conor E. Ramalingam, Suresh S. EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic? |
| title | EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic? |
| title_full | EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic? |
| title_fullStr | EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic? |
| title_full_unstemmed | EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic? |
| title_short | EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic? |
| title_sort | egfr tyrosine kinase inhibitors (tkis) for adjuvant therapy of early-stage non-small cell lung cancer (nsclc): ready for the clinic? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653125/ https://www.ncbi.nlm.nih.gov/pubmed/33209593 http://dx.doi.org/10.21037/tlcr-2020-13 |
| work_keys_str_mv | AT steuerconore egfrtyrosinekinaseinhibitorstkisforadjuvanttherapyofearlystagenonsmallcelllungcancernsclcreadyfortheclinic AT ramalingamsureshs egfrtyrosinekinaseinhibitorstkisforadjuvanttherapyofearlystagenonsmallcelllungcancernsclcreadyfortheclinic |